Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker BCAX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Ryan Cohlhepp President, COO & Interim CEO, Director | BCAX Bicara Therapeutics Inc. | Sale | 3,442 | $23.43 | $80.6K Sale | Form 4 ↗ |
| Sep 8, 2026 | Ryan Cohlhepp President, COO & Interim CEO, Director | BCAX Bicara Therapeutics Inc. | Sale | 14,058 | $22.77 | $320.1K Sale | Form 4 ↗ |
| Aug 10, 2026 | Ivan Hyep Chief Financial Officer | BCAX Bicara Therapeutics Inc. | Sale | 12,500 | $27.97 | $349.6K Sale | Form 4 ↗ |
| Aug 10, 2026 | Claire Mazumdar Chief Executive Officer, Director | BCAX Bicara Therapeutics Inc. | Sale | 10,000 | $27.98 | $279.8K Sale | Form 4 ↗ |
| Aug 10, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 18,750 | $27.98 | $524.6K Sale | Form 4 ↗ |
| Jul 10, 2026 | Claire Mazumdar Chief Executive Officer, Director | BCAX Bicara Therapeutics Inc. | Sale | 28 | $29.68 | $831 Sale | Form 4 ↗ |
| Jul 10, 2026 | Claire Mazumdar Chief Executive Officer, Director | BCAX Bicara Therapeutics Inc. | Sale | 9,972 | $28.42 | $283.4K Sale | Form 4 ↗ |
| Jul 9, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 536 | $29.00 | $15.5K Sale | Form 4 ↗ |
| Jul 8, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 1,075 | $30.35 | $32.6K Sale | Form 4 ↗ |
| Jul 8, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 4,306 | $29.80 | $128.3K Sale | Form 4 ↗ |
| Jul 8, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 22,833 | $28.76 | $656.7K Sale | Form 4 ↗ |
| Jul 8, 2026 | Ivan Hyep Chief Financial Officer | BCAX Bicara Therapeutics Inc. | Sale | 830 | $30.31 | $25.2K Sale | Form 4 ↗ |
| Jul 8, 2026 | Ivan Hyep Chief Financial Officer | BCAX Bicara Therapeutics Inc. | Sale | 4,413 | $29.82 | $131.6K Sale | Form 4 ↗ |
| Jul 8, 2026 | Ivan Hyep Chief Financial Officer | BCAX Bicara Therapeutics Inc. | Sale | 22,757 | $28.60 | $650.9K Sale | Form 4 ↗ |
| May 21, 2026 | Ivan Hyep Chief Financial Officer | BCAX Bicara Therapeutics Inc. | Sale | 9,200 | $20.42 | $187.9K Sale | Form 4 ↗ |
| May 18, 2026 | Claire Mazumdar Chief Executive Officer, Director | BCAX Bicara Therapeutics Inc. | Sale | 2,978 | $20.35 | $60.6K Sale | Form 4 ↗ |
| May 18, 2026 | Claire Mazumdar Chief Executive Officer, Director | BCAX Bicara Therapeutics Inc. | Sale | 12,022 | $19.96 | $240.0K Sale | Form 4 ↗ |
| May 15, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 4,500 | $20.29 | $91.3K Sale | Form 4 ↗ |
| May 15, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 8,000 | $20.29 | $162.3K Sale | Form 4 ↗ |
| Apr 27, 2026 | David Raben Chief Medical Officer | BCAX Bicara Therapeutics Inc. | Sale | 5,500 | $22.88 | $125.8K Sale | Form 4 ↗ |
| Apr 21, 2026 | Ivan Hyep Chief Financial Officer | BCAX Bicara Therapeutics Inc. | Sale | 9,200 | $23.00 | $211.6K Sale | Form 4 ↗ |
| Apr 20, 2026 | Claire Mazumdar Chief Executive Officer, Director | BCAX Bicara Therapeutics Inc. | Sale | 15,000 | $23.61 | $354.1K Sale | Form 4 ↗ |
| Apr 15, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 4,500 | $23.01 | $103.5K Sale | Form 4 ↗ |
| Apr 15, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 8,000 | $23.01 | $184.1K Sale | Form 4 ↗ |
| Mar 25, 2026 | David Raben Chief Medical Officer | BCAX Bicara Therapeutics Inc. | Sale | 5,500 | $18.95 | $104.2K Sale | Form 4 ↗ |
| Mar 23, 2026 | Ivan Hyep Chief Financial Officer | BCAX Bicara Therapeutics Inc. | Sale | 9,200 | $18.52 | $170.4K Sale | Form 4 ↗ |
| Mar 20, 2026 | Claire Mazumdar Chief Executive Officer, Director | BCAX Bicara Therapeutics Inc. | Sale | 1,596 | $18.95 | $30.2K Sale | Form 4 ↗ |
| Mar 19, 2026 | Claire Mazumdar Chief Executive Officer, Director | BCAX Bicara Therapeutics Inc. | Sale | 6,905 | $18.78 | $129.7K Sale | Form 4 ↗ |
| Mar 18, 2026 | Claire Mazumdar Chief Executive Officer, Director | BCAX Bicara Therapeutics Inc. | Sale | 6,499 | $18.84 | $122.4K Sale | Form 4 ↗ |
| Mar 16, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 4,500 | $19.66 | $88.5K Sale | Form 4 ↗ |
| Mar 16, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 8,000 | $19.66 | $157.3K Sale | Form 4 ↗ |
| Mar 9, 2026 | Claire Mazumdar Chief Executive Officer, Director | BCAX Bicara Therapeutics Inc. | Sale | 36,766 | $19.17 | $704.8K Sale | Form 4 ↗ |
| Mar 6, 2026 | Claire Mazumdar Chief Executive Officer, Director | BCAX Bicara Therapeutics Inc. | Sale | 3,817 | $18.75 | $71.6K Sale | Form 4 ↗ |
| Mar 5, 2026 | Claire Mazumdar Chief Executive Officer, Director | BCAX Bicara Therapeutics Inc. | Sale | 1,786 | $18.74 | $33.5K Sale | Form 4 ↗ |
| Mar 4, 2026 | Claire Mazumdar Chief Executive Officer, Director | BCAX Bicara Therapeutics Inc. | Sale | 2,631 | $18.73 | $49.3K Sale | Form 4 ↗ |
| Mar 4, 2026 | Ivan Hyep Chief Financial Officer | BCAX Bicara Therapeutics Inc. | Sale | 2,963 | $18.25 | $54.1K Sale | Form 4 ↗ |
| Mar 4, 2026 | David Raben Chief Medical Officer | BCAX Bicara Therapeutics Inc. | Sale | 16,300 | $18.52 | $301.9K Sale | Form 4 ↗ |
| Mar 3, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 4,500 | $18.16 | $81.7K Sale | Form 4 ↗ |
| Mar 3, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 12,892 | $18.16 | $234.1K Sale | Form 4 ↗ |
| Mar 3, 2026 | Ivan Hyep Chief Financial Officer | BCAX Bicara Therapeutics Inc. | Sale | 13,555 | $18.22 | $247.0K Sale | Form 4 ↗ |
| Mar 3, 2026 | David Raben Chief Medical Officer | BCAX Bicara Therapeutics Inc. | Sale | 200 | $18.45 | $3,690 Sale | Form 4 ↗ |
| Feb 26, 2026 | Ra Capital Management, L.P. Director, 10% owner | BCAX Bicara Therapeutics Inc. | Buy | 300,000 | $16.00 | $4.8M Buy | Form 4 ↗ |
| Feb 25, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 523 | $18.04 | $9,435 Sale | Form 4 ↗ |
| Feb 25, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 3,108 | $18.04 | $56.1K Sale | Form 4 ↗ |
| Jan 22, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 3,828 | $18.10 | $69.3K Sale | Form 4 ↗ |
| Jan 22, 2026 | Ivan Hyep Chief Financial Officer | BCAX Bicara Therapeutics Inc. | Sale | 1,882 | $18.15 | $34.2K Sale | Form 4 ↗ |
| Jan 15, 2026 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 149 | $18.02 | $2,685 Sale | Form 4 ↗ |
| Dec 22, 2025 | Ivan Hyep Chief Financial Officer | BCAX Bicara Therapeutics Inc. | Sale | 9,200 | $18.31 | $168.5K Sale | Form 4 ↗ |
| Dec 15, 2025 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 4,500 | $18.68 | $84.1K Sale | Form 4 ↗ |
| Dec 15, 2025 | Ryan Cohlhepp President and COO, Director | BCAX Bicara Therapeutics Inc. | Sale | 8,000 | $18.68 | $149.4K Sale | Form 4 ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 4:59 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances